Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial source : Www.athira.com save search
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Published: 2021-10-22 (Crawled : 12:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 9.45%
H: 9.46%
C: 1.61%
disease alzheimer phase 2 ath-1017 trial enroll alzheimer’s alzheimer's disease alzheimer's
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-09-29 (Crawled : 11:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 0.75%
H: 1.17%
C: -0.75%
disease alzheimer phase 2 ath-1017 clinical trials phase 2/3 trials trial conference alzheimer’s alzheimer's disease alzheimer's
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
Published: 2021-07-06 (Crawled : 12:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 1.15%
H: 5.59%
C: 4.17%
disease alzheimer clinical trials trial ath-1017 alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.